Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection

AIDS

Volumn 18, Issue 3, 2004, Pages 365-370

  Phillips, Andrew N ^a   Walker, A Sarah ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Endpoint; HIV; Intention to treat; Randomized controlled trials; Viral load; Virologic failure

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LYMPHOCYTE COUNT; NEUROTOXICITY; PRIORITY JOURNAL; RASH; REVIEW; TOXICITY; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT FAILURE; VIRAL LOAD;

EID: 1642363897     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200402200-00001     Document Type: Review

References (29)

1. Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate endpoints in AIDS clinical trials. JAMA 2001, 285:777-784.
2. Kirk O, Pedersen C, Law M, Gulick RM, Moyle G, Montaner J, et al. Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antiviral Ther 2002, 7:271-281.
3. DiRienzo AG, DeGruttola V. Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142. Control Clin Trials 2003, 24:122-134.
4. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://www.aidsinfo.nih.gov
5. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003, 4(Suppl 1):1-41.
6. van Leth F, Hassink E, Phanuphak P, Miller S, Gazzard B, Cahn P, et al. for the 2NN study group. Results of the 2NN Study: A randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 176].
7. U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. Oct 2002. http://www.fda.gov/cder/ guidance/index.htm
8. Robbins G, Shafer R, Smeaton L, De Gruttola V, Pettinelli C, Snyder S, et al. Antiretroviral strategies in naïve HIV+ subjects: comparison of sequential 3-drug regimens (ACTG 384). XIV International Conference on AIDS. Barcelona, July 2002 [abstract LbOr20A).
9. Mazen Y, Pozniak AL, Pillay D, Mandalia S, Wildfire A, Gazzard BG. Evidence for low-level viral replication (<50 copies/mL) predicts eventual virological failure. Eighth Annual Conference of the British HIV Association. York, UK, April 2002 [abstract 011].
10. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002, 16:1967-1969.
11. Moore AL, Youle M, Lipman M, Cozzi-Lepri A, Lampe F, Madge S, et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS 2002, 16:615-618.
12. Staszewski S, Sabin C, Dauer B, Cozzi Lepri A, Phillips AN. Definition of loss of virologic response in trials of antiretroviral drugs. AIDS 2003, 17:1997.
13. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. ICONA Study Group. AIDS 2000, 14:499-507.
14. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001, 15:185-194.
15. Dragsted U, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, et al. for the MaxCmin1 trial group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 trial. J Infect Dis 188:635-642.
16. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-868.
17. Staszewski S, Miller V, Sabin CA, Carlebach A, Berger A-M, Weidemann E, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999, 13:367-373.
18. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chron Dis 1967, 20:637-648.
19. White IR, Walker AS, Babiker AG, Darbyshire JH. Impact of treatment changes on the interpretation of the Concorde trial. AIDS 1997, 11:999-1006.
20. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001, 285:1155-1163.
21. HIV Surrogate Marker Collaborative Group. Human Immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate endpoints: a meta-analysis. AIDS Res Hum Retroviruses 2000, 16:1123-1133.
22. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996, 335:1081-1090.
23. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
24. Delta Co-ordinating Committee. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
25. K Squires, Thiry A, Giordano M et al. Atazanavir (ATV) qd and efavirenz (EFV) qd with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (A1424-034). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September, 2002 [abstract 1076].
26. Vibhagool A, Cahn P, Schechter M, Soto-Ramirez L, Montroni M, Smaill F, et al. Abacavir/Combivir (ABC/COM) is comparable to indinavir/Combivir (IDV/COM) in HIV-1-infected antiretroviral therapy naïve adults: Preliminary results of a 48-week open-label study (CNA 3014). first IAS Conference on HIV Pathogen-esis and Treatment. Buenos Aires, July 2001 [abstract 63].
27. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P. et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346:2039-2046.
28. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999, 341:1865-1873.
29. Schurmann D, Gathe J, Sanne I, Wood R. Efficacy and safety of GW433908/ritonavir once daily in therapy-naive subjects, 48 weeks results: The SOLO study. Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, November 2002 [abstract PL14.4].